KRAS and neoplasm: Tumors treated with sotorasib achieved a TGI of 74% with no significant difference from those treated with the chimeric siRNA; however, a combination treatment strategy of sotorasib and MYC/KRAS chimeric siRNA administration led to highly significant responses in nearly every tumor with a peak TGI of 132%.